A little over a decade ago, ND Stevenson dreamt up a spunky shapeshifter with short

The Workers United union said on Monday that thousands of employees at hundreds of Starbucks stores will walk

UK lawmakers will investigate whether firms are doing enough to tackle pervasive sexist attitudes in the finance industry

Former president Donald Trump was recorded in 2021 flaunting his possession of classified military documents, according to audio obtained by CNN. In the recording, which allegedly came from a meeting at Mr Trump’s Bedminster golf club and estate, the former president can be heard audibly shuffling documents and describing his “big pile of papers” to associates. “These are the papers,” Mr Trump says at one point, refering to a military document concerning Iran and US military joint chief of staff Mark Milley. “This was done by the military and given to me.” “They presented me this—this is off the record,” Mr Trump appears to say at another point in the recording, describing the information he is showing to others as “highly confidential” and “secret.” Mr Trump was indicted earlier this month and charged with 37 counts related to his alleged mishandling of classified documents after leaving the White House, including willful retention of national defense secrets in violation of the Espionage Act, conspiracy to obstruct justice, corruptly concealing documents, concealing documents in a federal investigation, scheme to conceal, and making false statements. In May, CNN reported that among the evidence prosecutors used to build their case against the former president was an audio recording of a summer 2021 meeting, in which Mr Trump allegedly acknowledged holding onto a classified Pentagon document detailing potential battle plans against Iran. In the indictment, prosecutors quoted Mr Trump as saying the plan was “highly confidential,” “secret,” and that “as president, I could have declassified it.” The ex-president was then supposedly recorded adding: “Now I can’t, you know, but it’s still a secret.” In an interview with Fox News, Mr Trump denied possessing such a document. “That was a massive amount of papers and everything else talking about Iran and other things,” he said. “And it may have been held up or it may not but that was not a document. I did not have a document per se.” This is a breaking news story and will be updated with new information. Read More Rape accuser files new lawsuit as Trump seethes over 2024 flop – live Where do Donald Trump’s family stand on him running in 2024? Trump revealed to have tweeted classified image from spy satellite

The right-wing media universe is maturing — and finding great success — beyond typical news commentary.

The fourth and final season of thriller series ‘Jack Ryan’, which follows the character played by TV’s beloved John Krasinski is set to release soon

Jonathan Taylor is not going to Dallas.

How social media reacted to Manchester City's 1-1 Premier League draw with Liverpool.

Pete Alfonso hit a two-run homer

A new survey has found that nearly half of adults in the United States are interested in taking prescription drugs for weight loss, such as Ozempic or Wegovy. In a KFF health tracking poll published on 3 August, researchers reported that 45 per cent of adults said they’d be interested in taking a “safe and effective” prescription drug for weight loss. Meanwhile, seven in 10 adults said they’ve heard at least “a little” about a new class of drugs being used for weight loss, with about one in five saying they have heard “a lot” about these drugs. Ozempic is a type 2 diabetes medication known for its weight loss side effects. Similar semaglutide injections, such as Wegovy and Mounjaro, have been specifically approved for the treatment of obesity and weight loss. This class of drugs called GLP-1 agonists works by mimicking a hormone called glucagon-like peptide 1 (GLP-1), regulating blood sugar levels and slowing down the rate at which food leaves the stomach to create the feeling of fullness. Of the US adults surveyed, older groups were some of the most aware of prescription weight loss drugs, with 76 per cent being those who have been told by a doctor in the past five years that they are overweight or obese. Nearly 60 per cent of those surveyed said they were currently trying to lose weight as well. While there was an overall interest in taking a prescription weight loss drug, that interest significantly decreased when people were asked whether they would take the medication as a routine injection. Only 16 per cent of adults said they would still take Ozempic or Wegovy, even if it wasn’t covered by their health insurance and was not specifically approved by the US Food and Drug Administration for weight loss. In fact, most people believed that insurance companies should cover the cost of weight loss drugs for adults who are overweight or obese, with an overwhelming 80 per cent of adults. Additionally, a large majority of adults believed the substantial profits that pharmaceutical companies have made from increased demand for weight loss drugs is a major factor contributing to the cost of injections like Ozempic and Wegovy. According to Novo Nordisk, the pharmaceutical company behind these prescription drugs for diabetes and weight loss, the list price for Ozempic can cost $935.77 per month without health insurance. Although the majority of adults said they trust pharmaceutical companies like Novo Nordisk to provide “reliable information” about safety and side effects of GLP-1 agonists, only 22 per cent said they trust these companies to price their products fairly. The FDA has listed the most common side effects of taking Wegovy as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, and digestive disorders. More serious complications can occur from use of Wegovy or Mounjaro, such as the “potential risk of thyroid C-cell tumours,” pancreatitis, gallbladder problems, acute kidney injury, increased heart rate, and suicidal behaviour or thinking. Taking Ozempic can also lead to possible thyroid tumours, including cancer, pancreatitis, changes in vision, and kidney and gallbladder problems. Recently, several patients reported suffering from severe gastroparesis, also known as stomach paralysis, after taking the prescription weight loss medications. In a report from CNN, two people claimed that their “stomachs are paralysed” after taking Ozempic. “I wish I never touched it. I wish I’d never heard of it in my life,” Joanie Knight, a 37-year-old from Louisiana, told CNN. “This medicine made my life hell. So much hell. It has cost me money. It cost me a lot of stress; it cost me days and nights and trips with my family. It’s cost me a lot, and it’s not worth it. The price is too high.” One woman was also diagnosed with cyclic vomiting syndrome, which causes her to throw up multiple times a day. “I’ve almost been off Ozempic for a year, but I’m still not back to my normal,” said Emily Wright, a 38-year-old teacher from Toronto. Shortly after the report, the FDA shared in a statement with The Independent that it has become aware of stomach paralysis occurring among patients taking the medications. “The FDA has received reports of gastroparesis with semaglutide and liraglutide, of which some documented the adverse event as not recovered after discontinuation of the respective product at the time of the report,” the agency said. However, officials clarified that they were unable to determine whether taking Ozempic or Wegovy was the cause of stomach paralysis, or if it was caused by a different issue. “Gastroparesis can be a complication of diabetes that is related to long-standing or poorly controlled disease, further complicating the ability to determine what role the drugs played in the reported events,” the FDA added. In response to reports of stomach paralysis, drug manufacturer Novo Nordisk noted that these medications have been used to treat type 2 diabetes “for more than 15 years”, and for the “treatment of obesity” for eight years. “Semaglutide has been extensively examined in robust clinical development programs, large real world evidence studies and has cumulatively over 9.5 million patient years of exposure,” a spokesperson for Novo Nordisk said in a statement to The Independent. “Gastrointestinal (GI) events are well-known side effects of the GLP-1 class. For semaglutide, the majority of GI side effects are mild to moderate in severity and of short duration. GLP-1’s are known to cause a delay in gastric emptying, as noted in the label of each of our GLP-1 RA medications. Symptoms of delayed gastric emptying, nausea and vomiting are listed as side effects.” Read More Obese people on weight-loss jabs ‘should be prepared to stay on them for life’ Ozempic users report stomach paralysis as weight loss drug side effect: ‘I wish I never touched it’ Sharon Osbourne says she was ‘nauseous’ for weeks after taking Ozempic to lose weight Sharon Osbourne reveals what Ozempic did to her when she was taking it Ozempic users report stomach paralysis as side effect: ‘I wish I never touched it’ Lorraine Candy: ‘Perimenopausal rage made me unravel’

Lana Del Rey reportedly has put an end to recent engagement rumors herself

American golfer Bryson DeChambeau told CNN he "feels bad" for PGA Tour players that did not take the "risk" he did by joining the breakaway LIV Golf, in the wake of the shock reconciliation between the warring tours on Tuesday.